Athenex, Inc. (ATNX)

Trade ATNX now with
6/13/2020 10:12:26 AM Athenex Oncology Launches Facing MBC Together Campaign
5/29/2020 8:15:31 AM Athenex Presents Interim Data From Oral Paclitaxel Phase II Study In Cutaneous Angiosarcom
4/9/2020 7:15:12 AM Athenex Says On Track To Submit NDA In Accordance With FDA's Guidance
3/9/2020 7:04:34 AM Athenex Reports FDA Acceptance For Filing Of US NDA For Tirbanibulin Ointment
9/4/2019 7:07:10 AM Athenex Names Daniel Lang MD To Lead TCR-T Immunotherapy Operations And Support Corporate Development Strategy
6/28/2019 7:06:20 AM Athenex Strategically Expands Presence In Europe And Latin America
6/24/2019 7:05:17 AM Athenex: FDA Allows IND Application For PT01 For Patients With Advanced Malignancies
3/11/2019 7:12:34 AM Athenex Q4 Net Loss Attributable To Athenex $27.1 Mln Or $0.41/Shr Vs Loss Of $28.3 Mln Or $0.49/Shr Last Year
1/3/2019 7:13:00 AM Chongqing Jingdong Pharma, Athenex Announce Strategic Partnership And Licensing Deal To Develop KX2-391 In China
12/26/2018 7:01:41 AM Athenex Pharmaceutical Launches Levothyroxine Sodium For Injection
12/11/2018 7:07:12 AM Athenex Announces Positive Second Cohort Results Of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial In Gastric Cancer
11/29/2018 7:12:24 AM Athenex Enters Agreement With PharmaEssentia To License Rights To Develop, Commercialize Oradoxel
11/14/2018 7:05:05 AM Athenex Q3 Net Loss Attributable To Athenex $46.2 Mln Or $0.70/Shr Vs Loss Of $23.3 Mln Or $0.41/Shr Last Year
10/29/2018 7:03:19 AM Athenex Reports FDA Allowance Of Investigational NDA Of Eribulin ORA To Begin Clinical Trials
10/22/2018 7:18:58 AM Athenex Presents Encouraging Clinical Trial Efficacy And Safety Results Of Oraxol In Metastatic Breast Cancer
10/16/2018 8:08:33 AM Athenex To Present Positive Data Of Oraxol Clinical Trial In Breast Cancer At The ESMO 2018 Congress
10/15/2018 7:07:25 AM Athenex, Xiangxue Life Sciences Announce Preliminary Results Of TAEST Showed Encouraging Positive Clinical Signals
9/5/2018 7:09:43 AM Athenex Says DSMB Congratulated On Rapid Patient Recruitment, Promising Results Achieved In Oraxol 001 Phase III Trial